Cardiometabolic & kidneySecondary analysis
Residual Inflammatory Risk of Heart Failure and Atherosclerotic Cardiovascular Disease (CVD) in Diabetes
- Secondary analysis of the Look AHEAD randomised trial
Authors' conclusion
Among adults with T2D and overweight/obesity, IL-6 identified residual inflammatory risk of incident HF, particularly among adults with no CVD history. An ILI targeting weight loss reduced IL-6 over 1-year of follow-up.
Study context
- Population
- Adults with T2D and overweight/obesity in the Look AHEAD trialHigh-sensitivity C-reactive protein (hs-CRP) n = 1,902
- Comparison
- Intensive lifestyle intervention (ILI) vs Diabetes support and education
- Primary endpoint
- Risk of ASCVD and incident HF by hs-CRP and IL-6
Primary result
Incident HF by IL-6 (per 1-SD higher log[IL-6])
Hazard ratio
1.43
95% CI 1.16–1.75
Per 1-SD higher log[IL-6]
HR 1.43 (95% CI 1.16–1.75)
Per 1-SD higher log[IL-6], as printed
As reported in the abstract
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Incident HF by IL-6, no CVD history (subgroup) | 1.92 (1.38–2.66) | ||
| 0.20.5125Hazard ratio (log scale) |
| Outcome | ILI | Diabetes support and education | Estimate | P value |
|---|---|---|---|---|
| Change in IL-6 · 1 year | −28.7% | −11.8% | P = 0.01 |
- Incident heart failure (HF) by IL-6, no CVD history (subgroup): IL-6 × CVD history interaction P < 0.05
Baseline hs-CRP and IL-6 · median baseline
- Median hs-CRP
- 4.04 mg/L
- Median IL-6
- 2.07 pg/mL
Original publication
Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes. JACC Heart Fail. Published 2 September 2026. doi:10.1016/j.jchf.2026.103296
Summarised from the published abstract; every number is checked against it